Compare ACADIA Pharmaceuticals Inc. (ACAD) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs SOLAI Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.7 (market cap $5.07B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 303.8× SOLAI Limited's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | SLAI | |
|---|---|---|
Market Cap | $5.07B | $16.69M |
Sector | Health | Technology |
52-Week High | $29.41 | $26.74 |
52-Week Low | $20.06 | $2.74 |
Enterprise Value | $4.19B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
SLAI trades at $3.72 with no recent price movement. The company faces severe financial distress with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Technical indicators show a bullish signal despite fundamental weakness. Recent developments include a 7:1 reverse stock split effective July 2026 and NYSE delisting proceedings initiated in July 2026 following multiple compliance notices.
Investment outlook remains highly speculative given the company's financial deterioration and exchange delisting risk. The acquisition of NEURALAND stake and Solode Neo product launch provide potential growth catalysts, but current negative profitability and cash flow challenges outweigh near-term opportunities. Analyst consensus shows 100% hold rating with no buy recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
